Metabolites profile of colorectal cancer cells at different stages

Objective: The aim of this study is to characterize the metabolite profiles of colorectal cancer (CRC) cells of different stages of the disease to understand the pathophysiological changes that may help to identify prevention strategies as well as the sites for potential therapeutic drug actions. Me...

Full description

Bibliographic Details
Main Authors: Ab-Rahim, S. (Author), Jamal A, R.A (Author), Mazlan, M. (Author), Nathan, S. (Author), Ngah, W.Z.W (Author), Yusof, H.M (Author)
Format: Article
Language:English
Published: Innovare Academics Sciences Pvt. Ltd 2019
Subjects:
Online Access:View Fulltext in Publisher
View in Scopus
LEADER 04105nam a2200817Ia 4500
001 10.22159-ijap.2019.v11s1.T0051
008 220121s2019 CNT 000 0 und d
020 |a 09757058 (ISSN) 
245 1 0 |a Metabolites profile of colorectal cancer cells at different stages 
260 0 |b Innovare Academics Sciences Pvt. Ltd  |c 2019 
650 0 4 |a 1,2,4 nonadecanetriol 
650 0 4 |a 13 oxo 9 octadecenoic acid 
650 0 4 |a 2 methylbutyroylcarnitine 
650 0 4 |a acetylcarnitine 
650 0 4 |a amillaripin 
650 0 4 |a armillaripin 
650 0 4 |a Article 
650 0 4 |a cancer prevention 
650 0 4 |a Cancer stages 
650 0 4 |a cancer staging 
650 0 4 |a chemical analysis 
650 0 4 |a Colorectal cancer 
650 0 4 |a colorectal cancer cell line 
650 0 4 |a comparative study 
650 0 4 |a DLD-1 cell line 
650 0 4 |a drug identification 
650 0 4 |a drug mechanism 
650 0 4 |a flavine adenine nucleotide 
650 0 4 |a flavine mononucleotide 
650 0 4 |a glucose 6 phosphate 
650 0 4 |a HCT 116 cell line 
650 0 4 |a HCT 15 cell line 
650 0 4 |a hexadeconoic acid 
650 0 4 |a HT-29 cell line 
650 0 4 |a human 
650 0 4 |a human cell 
650 0 4 |a lactic acid 
650 0 4 |a leucine 
650 0 4 |a liquid chromatography-mass spectrometry 
650 0 4 |a lumichrome 
650 0 4 |a lysope 
650 0 4 |a metabolic fingerprinting 
650 0 4 |a metabolomics 
650 0 4 |a Metabolomics 
650 0 4 |a methanol 
650 0 4 |a methionine 
650 0 4 |a muricatacin 
650 0 4 |a palmitic acid 
650 0 4 |a pantothenic acid 
650 0 4 |a pathophysiology 
650 0 4 |a phenylalanine 
650 0 4 |a phytosphingosine 
650 0 4 |a pipericine 
650 0 4 |a protein 
650 0 4 |a riboflavin 
650 0 4 |a software 
650 0 4 |a SW1116 cell line 
650 0 4 |a SW480 cell line 
650 0 4 |a unclassified drug 
650 0 4 |a upregulation 
650 0 4 |a water 
856 |z View Fulltext in Publisher  |u https://doi.org/10.22159/ijap.2019.v11s1.T0051 
856 |z View in Scopus  |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073502138&doi=10.22159%2fijap.2019.v11s1.T0051&partnerID=40&md5=a9ed72467b09073178175f9203fc5ad4 
520 3 |a Objective: The aim of this study is to characterize the metabolite profiles of colorectal cancer (CRC) cells of different stages of the disease to understand the pathophysiological changes that may help to identify prevention strategies as well as the sites for potential therapeutic drug actions. Methods: Six CRC cell lines of different stages (classified using the Dukes classification) were used, and they are SW 1116 (stage A), HT 29 and SW 480 (stage B), HCT 15 and DLD-1 (stage C), and HCT 116 (stage D). Metabolites were extracted using methanol and water, and metabolic profiling was performed using liquid chromatography-mass spectrometry. Mass profiler professional software was used for statistical analysis. Results: There were 111,096 compounds detected across the samples, and 24 metabolites were identified to be significantly different between the CRC stages. Most notably, there were eight metabolites that were significantly upregulated in the more advanced stages (B, C, and D) compared with Stage A. These metabolites include flavin mononucleotide, l-methionine, muricatacin, amillaripin, 2-methylbutyroylcarnitine, lumichrome, hexadeconoic acid, and lysoPE (0:0/16:0). Conclusion: This study showed that the expressions of metabolites at different stages of CRC were different, which represent the metabolic changes occurring as CRC advances. The knowledge may help identify biomarkers for the staging of CRC, which could improve its prognosis as well as provide a basis for the development of therapeutic interventions. © 2019 The Authors. 
700 1 0 |a Ab-Rahim, S.  |e author  
700 1 0 |a Jamal A, R.A.  |e author  
700 1 0 |a Mazlan, M.  |e author  
700 1 0 |a Nathan, S.  |e author  
700 1 0 |a Ngah, W.Z.W.  |e author  
700 1 0 |a Yusof, H.M.  |e author  
773 |t International Journal of Applied Pharmaceutics  |x 09757058 (ISSN)  |g 11 Special Issue 5, 66-70